THE USE OF BOTULINUM TOXIN TYPE A FOR THE TREATMENT OF CHRONIC MIGRAINE: A literature review.
DOI:
https://doi.org/10.61164/rsv.v7i1.1958Abstract
ABSTRACT: INTRODUCTION: OnabotulinumtoxinA (OnaB-A) has been emerging as a new preventive treatment therapy for chronic migraine, emerging in the clinical observation phase, which is currently being supported by evidence from more than a decade of research and data clinicians in the real world. At the present time, the ability to predict responses is limited, although patients are clinically significant, there is still a way to go. This review briefly summarizes the updates on the use of onabotulinumtoxinA in the preventive therapy of chronic migraine, as well as clarifies the main disagreements regarding the dose, types of responders and initiation of treatment. OBJECTIVE: To analyze updates on the use of onabotulinumtoxinA for the treatment of chronic migraine. METHODOLOGY: This is a descriptive literature review, with a qualitative approach, carried out in the following databases: PubMed and VHL, using the following search terms: OnabotulinumtoxinA (OnaB-A) and Chronic Migraine. Articles in the following languages were included: French, English and Portuguese. CONCLUSION: Therefore, it is concluded that the application of OnabotulinumtoxinA reduces the number of headache days and the intensity of pain, although it is still considered recent, BT-A is a prophylactic, preventive, safe and effective treatment for chronic migraine.
Keywords: Botulinum toxin A, OnabotulinumtoxinA (OnaB-A), Chronic migraine and Chronic Migraine.
References
Bendtsen, L., et al. Diretriz sobre o uso de onabotulinumtoxinA na enxaqueca crônica: uma declaração de consenso da European Headache Federation. J Headache Pain 19, 91 (2018). https://doi.org/10.1186/s10194-018-0921-8 DOI: https://doi.org/10.1186/s10194-018-0921-8
Blumenfeld, A. M., et al (2019). Effects of onabotulinumtoxinA treatment for chronic migraine on common comorbidities including depression and anxiety. Journal of neurology, neurosurgery, and psychiatry, 90(3), 353–360. https://doi.org/10.1136/jnnp-2018-319290 DOI: https://doi.org/10.1136/jnnp-2018-319290
Boudreau, G., et al (2022). OnabotulinumtoxinA Improves Quality of Life in Chronic Migraine: The PREDICT Study. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 49(4), 540–552. https://doi.org/10.1017/cjn.2021.153 DOI: https://doi.org/10.1017/cjn.2021.153
Caronna, E., et al (2018). OnabotulinumtoxinA: An Effective Tool in the Therapeutic Arsenal for Chronic Migraine With Medication Overuse. Frontiers in neurology, 9, 808. https://doi.org/10.3389/fneur.2018.00808 DOI: https://doi.org/10.3389/fneur.2018.00808
Colhado, O. C. G., et al (2009). Toxina botulínica no tratamento da dor. Revista Brasileira de Anestesiologia, 59, 366-381.
Dodick, D. W., et al (2019). Early onset of effect of onabotulinumtoxinA for chronic migraine treatment: Analysis of PREEMPT data. Cephalalgia : an international journal of headache, 39(8), 945–956. https://doi.org/10.1177/0333102418825382 DOI: https://doi.org/10.1177/0333102418825382
Frampton, J. E., & Silberstein, S. (2018). OnabotulinumtoxinA: A Review in the Prevention of Chronic Migraine. Drugs, 78(5), 589–600. https://doi.org/10.1007/s40265-018-0894-6 DOI: https://doi.org/10.1007/s40265-018-0894-6
Gandolfi, M., et al (2019). A Prospective Observational Cohort Study on Pharmacological Habitus, Headache-Related Disability and Psychological Profile in Patients with Chronic Migraine Undergoing OnabotulinumtoxinA Prophylactic Treatment. Toxins, 11(9), 504. https://doi.org/10.3390/toxins11090504 DOI: https://doi.org/10.3390/toxins11090504
Grazzi, L., et al (2023). A Single-Group Study on the Effect of OnabotulinumtoxinA in Patients with Chronic Migraine Associated with Medication Overuse Headache: Pain Catastrophizing Plays a Role. Toxins, 15(2), 86. https://doi.org/10.3390/toxins15020086 DOI: https://doi.org/10.3390/toxins15020086
Kim, K. M., et al (2021). Prevalence, Disability, and Management Patterns of Migraine in Korea: Nationwide Survey Data from 2009 and 2018. Journal of clinical neurology (Seoul, Korea), 17(1), 77–85. https://doi.org/10.3988/jcn.2021.17.1.77 DOI: https://doi.org/10.3988/jcn.2021.17.1.77
Matak, I., et al (2019). Mechanisms of Botulinum Toxin Type A Action on Pain. Toxins, 11(8), 459. https://doi.org/10.3390/toxins11080459 DOI: https://doi.org/10.3390/toxins11080459
Onan, D., et al (2022). OnabotulinumtoxinA Treatment in Chronic Migraine: Investigation of Its Effects on Disability, Headache and Neck Pain Intensity. Toxins, 15(1), 29. https://doi.org/10.3390/toxins15010029 DOI: https://doi.org/10.3390/toxins15010029
Ornello R, et al. Early Management of OnabotulinumtoxinA Treatment in Chronic Migraine: Insights from a Real-Life European Multicenter Study. Pain Ther. 2021 Jun;10(1):637-650. doi: 10.1007/s40122-021-00253-0. Epub 2021 Mar 28. PMID: 33778933; PMCID: PMC8119503.
Ornello, R., et al (2021). Early Management of OnabotulinumtoxinA Treatment in Chronic Migraine: Insights from a Real-Life European Multicenter Study. Pain and therapy, 10(1), 637–650. https://doi.org/10.1007/s40122-021-00253-0 DOI: https://doi.org/10.1007/s40122-021-00253-0
Ornello, R., et al (2022). Excellent Response to OnabotulinumtoxinA: Different Definitions, Different Predictors. International journal of environmental research and public health, 19(17), 10975. https://doi.org/10.3390/ijerph191710975 DOI: https://doi.org/10.3390/ijerph191710975
Santoro, A., et al (2020). Chronic migraine long-term regular treatment with onabotulinumtoxinA: a retrospective real-life observational study up to 4 years of therapy. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 41(7), 1809–1820. https://doi.org/10.1007/s10072-020-04283-y DOI: https://doi.org/10.1007/s10072-020-04283-y
Schiano di Cola F, et al 2019 Jul 10;10:678. Response Predictors in Chronic Migraine: Medication Overuse and Depressive Symptoms Negatively Impact Onabotulinumtoxin-A Treatment. doi: 10.3389/fneur.2019.00678. PMID: 31354606; PMCID: PMC6635602. DOI: https://doi.org/10.3389/fneur.2019.00678
Torrente, A., et al (2022). OnabotulinumtoxinA Modulates Visual Cortical Excitability in Chronic Migraine: Effects of 12-Week Treatment. Toxins, 15(1), 23. https://doi.org/10.3390/toxins15010023 DOI: https://doi.org/10.3390/toxins15010023
Torres-Ferrus, M., et al (2020). Influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinA. The journal of headache and pain, 21(1), 88. https://doi.org/10.1186/s10194-020-01157-8
Torres-Ferrus, M., et al (2020). Influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinA. The journal of headache and pain, 21(1), 88. https://doi.org/10.1186/s10194-020-01157-8 DOI: https://doi.org/10.1186/s10194-020-01157-8
Valente, M., et al (2021). Clinical and Neurophysiological Effects of Botulinum Neurotoxin Type A in Chronic Migraine. Toxins, 13(6), 392. https://doi.org/10.3390/toxins13060392 DOI: https://doi.org/10.3390/toxins13060392
Vikelis, M., et al (2018). Sustained onabotulinumtoxinA therapeutic benefits in patients with chronic migraine over 3 years of treatment. The journal of headache and pain, 19(1), 87. https://doi.org/10.1186/s10194-018-0918-3 DOI: https://doi.org/10.1186/s10194-018-0918-3
Wilderman, I., et al (2021). A Qualitative Study to Explore Patient Perspectives of Prophylactic Treatment with OnabotulinumtoxinA for Chronic Migraine. Pain and therapy, 10(2), 1523–1536. https://doi.org/10.1007/s40122-021-00316-2 DOI: https://doi.org/10.1007/s40122-021-00316-2
Winner P.K., et al. Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Patients with Chronic Migraine: Results of the COMPEL Study. Drug Saf. 2019 Aug;42(8):1013-1024. doi: 10.1007/s40264-019-00824-3. PMID: 31102144; PMCID: PMC6647876. DOI: https://doi.org/10.1007/s40264-019-00824-3
Zandieh, A., & Cutrer, F. M. (2022). OnabotulinumtoxinA in chronic migraine: is the response dose dependent?. BMC neurology, 22(1), 218. https://doi.org/10.1186/s12883-022-02742-x DOI: https://doi.org/10.1186/s12883-022-02742-x
